Malignancies Multiple
8
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (8)
Feasibility Pilot of AYA-PARTNER
PET/CT Imaging of GRPR Expression in Various Tumors
The Frequency of Anastomotic Leakage in Early and Delayed Oral Feeding Following Ileostomy Reversal Will be Compared
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
9-ING-41 in Patients with Advanced Cancers
Coronavirus Disease 2019 (COVID-19) Vaccination in Cancer Patients
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects